Univariate analysis of 2-year event-free and overall survival
| Variable . | Percentage event-free survival (SE) . | P (EFS) . | Percentage overall survival (SE) . | P (OS) . |
|---|---|---|---|---|
| Cohort | 40.2 (7.2) | 44.5 (8.0) | ||
| Stem cell source | ||||
| Related donor | 42.2 (12.7) | 50.1 (14.1) | ||
| Unrelated donor | 36.8 (11.1) | .909 | 39.5 (12.0) | .582 |
| CB | 41.7 (14.2) | 43.8 (16.5) | ||
| Disease | ||||
| ALL | 35.3 (11.6) | 36.8 (12.5) | ||
| AML | 41.7 (10.1) | .963 | 54.2 (10.2) | .986 |
| Other | 50 (20.4) | 50.0 (20.4) | ||
| History of previous BMT | ||||
| No BMT | 46.8 (11.6) | 52.1 (13) | ||
| Previous autologous BMT | 50 (20.4) | .539 | 62.5 (21.3) | .104 |
| Previous allogeneic BMT | 31.8 (9.9) | 32.7 (11.1) | ||
| No BMT | 46.8 (11.6) | 52.1 (13) | ||
| TBI-based BMT | 25 (10.8) | .232 | 23.4 (11) | .02 |
| Non–TBI-based BMT | 50.0 (14.4) | 62.5 (15.5) | ||
| Presence of acute or chronic GVHD | ||||
| GVHD | 50.0 (12.5) | .231 | 50.0 (14.8) | .380 |
| No GVHD | 39.6 (9.9) | 39.6 (10.5) | ||
| Chimerism by day 100 | ||||
| Full chimerism | 49.7 (8.6) | .016 | 49 (9.3) | .954 |
| Partial chimerism | 22.2 (14) | 44 (21) | ||
| Presence of detectable disease | ||||
| History of TBI | ||||
| Detectable disease | 20.0 (12.6) | .087 | 0 | .06 |
| No detectable disease | 50.0 (12.5) | 61.1 (12.6) | ||
| No previous TBI | ||||
| Detectable disease | 16.7 (15.2) | .038 | 0 | .010 |
| No detectable disease | 61.5 (13.5) | 62.7 (15.5) | ||
| Recipient CMV status | ||||
| CMV+ | 39.1 (10.2) | .908 | 44.7 (11.3) | .611 |
| CMV− | 40.0 (10.6) | 40.5 (11.5) | ||
| Recipient age, y | ||||
| > 10 | 44.0 (9.9) | .694 | 43.6 (10.9) | .885 |
| < 11 | 35.8 (10.3) | 45.6 (11.7) | ||
| Time to relapse after BMT 1 | ||||
| Less than 6 months | 33.3 (27.2) | 33.3 (27.2) | ||
| 6-12 months | 42.9 (18.7) | .988 | 42.9 (18.7) | .872 |
| More than 12 months | 33.3 (11.1) | 40.0 (13.0) | ||
| Donors for BMT 2 | ||||
| Same donor | 20.0 (17.9) | 40.0 (21.9) | ||
| Different donor | 38.5 (13.5) | .653 | 38.5 (13.5) | .377 |
| Auto/allo | 57.1 (18.7) | 68.6 (13.2) |
| Variable . | Percentage event-free survival (SE) . | P (EFS) . | Percentage overall survival (SE) . | P (OS) . |
|---|---|---|---|---|
| Cohort | 40.2 (7.2) | 44.5 (8.0) | ||
| Stem cell source | ||||
| Related donor | 42.2 (12.7) | 50.1 (14.1) | ||
| Unrelated donor | 36.8 (11.1) | .909 | 39.5 (12.0) | .582 |
| CB | 41.7 (14.2) | 43.8 (16.5) | ||
| Disease | ||||
| ALL | 35.3 (11.6) | 36.8 (12.5) | ||
| AML | 41.7 (10.1) | .963 | 54.2 (10.2) | .986 |
| Other | 50 (20.4) | 50.0 (20.4) | ||
| History of previous BMT | ||||
| No BMT | 46.8 (11.6) | 52.1 (13) | ||
| Previous autologous BMT | 50 (20.4) | .539 | 62.5 (21.3) | .104 |
| Previous allogeneic BMT | 31.8 (9.9) | 32.7 (11.1) | ||
| No BMT | 46.8 (11.6) | 52.1 (13) | ||
| TBI-based BMT | 25 (10.8) | .232 | 23.4 (11) | .02 |
| Non–TBI-based BMT | 50.0 (14.4) | 62.5 (15.5) | ||
| Presence of acute or chronic GVHD | ||||
| GVHD | 50.0 (12.5) | .231 | 50.0 (14.8) | .380 |
| No GVHD | 39.6 (9.9) | 39.6 (10.5) | ||
| Chimerism by day 100 | ||||
| Full chimerism | 49.7 (8.6) | .016 | 49 (9.3) | .954 |
| Partial chimerism | 22.2 (14) | 44 (21) | ||
| Presence of detectable disease | ||||
| History of TBI | ||||
| Detectable disease | 20.0 (12.6) | .087 | 0 | .06 |
| No detectable disease | 50.0 (12.5) | 61.1 (12.6) | ||
| No previous TBI | ||||
| Detectable disease | 16.7 (15.2) | .038 | 0 | .010 |
| No detectable disease | 61.5 (13.5) | 62.7 (15.5) | ||
| Recipient CMV status | ||||
| CMV+ | 39.1 (10.2) | .908 | 44.7 (11.3) | .611 |
| CMV− | 40.0 (10.6) | 40.5 (11.5) | ||
| Recipient age, y | ||||
| > 10 | 44.0 (9.9) | .694 | 43.6 (10.9) | .885 |
| < 11 | 35.8 (10.3) | 45.6 (11.7) | ||
| Time to relapse after BMT 1 | ||||
| Less than 6 months | 33.3 (27.2) | 33.3 (27.2) | ||
| 6-12 months | 42.9 (18.7) | .988 | 42.9 (18.7) | .872 |
| More than 12 months | 33.3 (11.1) | 40.0 (13.0) | ||
| Donors for BMT 2 | ||||
| Same donor | 20.0 (17.9) | 40.0 (21.9) | ||
| Different donor | 38.5 (13.5) | .653 | 38.5 (13.5) | .377 |
| Auto/allo | 57.1 (18.7) | 68.6 (13.2) |